Reviewer's report
Title:Systematic Investigation of gastrointestinal diseases in China (SILC):
validation of survey methodology
Version: 1Date:9 June 2009
Reviewer: Mattijs E Numans
Reviewer's report:
This is an interesting description of the methodology and first results of a large
survey on UPPER GI disease (although the title suggests that more than upper
GI disease might seriously be involved) combining information from
questionnaires as well as from endoscopy and lab results from the open
population. Essentially the main study is on GERD and it would be better to be
clearer about that and be more focused. It is very interesting that a large part of
the population was willing to be exposed to upper GI endoscopy and biopsies
without an indication. Overall the response rates are remarkably high.
The methodology followed seems sound to me. However, representing a more
general medical reading audience, I have difficulties with originality and
relevance of results and conclusions from this study published in this stage.
Level of interest: An article of limited interest
Quality of written English: Needs some language corrections before being
published
Statistical review: Yes, but I do not feel adequately qualified to assess the
statistics.
Declaration of competing interests:
I have advized on research and development of the RDQ for AstraZeneca
Sweden.
Reviewer's report
Title:Systematic Investigation of gastrointestinal diseases in China (SILC):
validation of survey methodology
Version: 1Date:9 June 2009
Reviewer: Mattijs E Numans
Reviewer's report:
This is an interesting description of the methodology and first results of a large
survey on UPPER GI disease (although the title suggests that more than upper
GI disease might seriously be involved) combining information from
questionnaires as well as from endoscopy and lab results from the open
population. Essentially the main study is on GERD and it would be better to be
clearer about that and be more focused. It is very interesting that a large part of
the population was willing to be exposed to upper GI endoscopy and biopsies
without an indication. Overall the response rates are remarkably high.
The methodology followed seems sound to me. However, representing a more
general medical reading audience, I have difficulties with originality and
relevance of results and conclusions from this study published in this stage.
Level of interest: An article of limited interest
Quality of written English: Needs some language corrections before being
published
Statistical review: Yes, but I do not feel adequately qualified to assess the
statistics.
Declaration of competing interests:
I have advized on research and development of the RDQ for AstraZeneca
Sweden.
Please review this paper.
user
Reviewer's report
Title:Systematic Investigation of gastrointestinal diseases in China (SILC):
validation of survey methodology
Version: 1Date:9 June 2009
Reviewer: Mattijs E Numans
Reviewer's report:
This is an interesting description of the methodology and first results of a large
survey on UPPER GI disease (although the title suggests that more than upper
GI disease might seriously be involved) combining information from
questionnaires as well as from endoscopy and lab results from the open
population. Essentially the main study is on GERD and it would be better to be
clearer about that and be more focused. It is very interesting that a large part of
the population was willing to be exposed to upper GI endoscopy and biopsies
without an indication. Overall the response rates are remarkably high.
The methodology followed seems sound to me. However, representing a more
general medical reading audience, I have difficulties with originality and
relevance of results and conclusions from this study published in this stage.
Level of interest: An article of limited interest
Quality of written English: Needs some language corrections before being
published
Statistical review: Yes, but I do not feel adequately qualified to assess the
statistics.
Declaration of competing interests:
I have advized on research and development of the RDQ for AstraZeneca
Sweden.
assistant